Daniel Stauder
Stock Analyst at Citizens
(4.24)
# 445
Out of 5,143 analysts
21
Total ratings
65%
Success rate
16.73%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daniel Stauder
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STXS Stereotaxis | Initiates: Market Outperform | $4 | $2.73 | +46.52% | 1 | Dec 16, 2025 | |
| AORT Artivion | Maintains: Market Outperform | $47 → $53 | $43.92 | +20.67% | 7 | Nov 7, 2025 | |
| ATRC AtriCure | Reiterates: Market Outperform | $60 | $40.02 | +49.93% | 6 | Apr 30, 2025 | |
| STIM Neuronetics | Maintains: Market Outperform | $3 → $7 | $2.20 | +218.18% | 1 | Mar 5, 2025 | |
| LMAT LeMaitre Vascular | Maintains: Buy | $105 → $110 | $85.74 | +28.29% | 4 | Feb 28, 2025 | |
| AXON Axon Enterprise | Reiterates: Market Outperform | $725 | $607.29 | +19.38% | 1 | Feb 26, 2025 | |
| AVNS Avanos Medical | Reiterates: Market Perform | n/a | $13.10 | - | 1 | May 7, 2024 |
Stereotaxis
Dec 16, 2025
Initiates: Market Outperform
Price Target: $4
Current: $2.73
Upside: +46.52%
Artivion
Nov 7, 2025
Maintains: Market Outperform
Price Target: $47 → $53
Current: $43.92
Upside: +20.67%
AtriCure
Apr 30, 2025
Reiterates: Market Outperform
Price Target: $60
Current: $40.02
Upside: +49.93%
Neuronetics
Mar 5, 2025
Maintains: Market Outperform
Price Target: $3 → $7
Current: $2.20
Upside: +218.18%
LeMaitre Vascular
Feb 28, 2025
Maintains: Buy
Price Target: $105 → $110
Current: $85.74
Upside: +28.29%
Axon Enterprise
Feb 26, 2025
Reiterates: Market Outperform
Price Target: $725
Current: $607.29
Upside: +19.38%
Avanos Medical
May 7, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $13.10
Upside: -